[2]Lin ZZ, Cai HW, Huang YF, et al. Prevalence of depression among university students in China: a systematic review and meta-analysis. BMC Psychol. 2025;13(1):373. Published 2025 Apr 11. doi:10.1186/s40359-025-02688-y
[4]Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 5th ed. Cambridge University Press; 2021. Chapter 1, 4, 6.
[5] Mi W, Yang F, Li H, et al. Efficacy, Safety, and Tolerability of Ansofaxine (LY03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Clinical Trial. Int J Neuropsychopharmacol. 2022;25(3):252-260. doi:10.1093/ijnp/pyab074
[6] Mi W, Di X, Wang Y, et al. A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder. Transl Psychiatry. 2023 May 10;13(1):163.